S. Samuel Weigt MD

Pulmonology•Los Angeles, CA

Critical Care Medicine, Interstitial Lung Diseases, Lung Transplantation Medicine

Assistant Professor, Medicine, UCLA School of Medicine

Join to View Full Profile

200 Med PlzSuite 365Los Angeles, CA 90095
Phone+1 310-825-8061
Fax+1 310-301-8751

Summary

Dr. S. Samuel Weigt is a pulmonologist in Los Angeles, CA and is affiliated with Ronald Reagan UCLA Medical Center. He received his medical degree from Creighton University School of Medicine and has been in practice 16 years. He specializes in interstitial lung diseases and lung transplantation medicine and is experienced in transplant pulmonology, lung transplantation, interstitial lung disease, and critical care medicine.

Education & Training

UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Pulmonary Disease and Critical Care Medicine, 2004 - 2007
UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Internal Medicine, 2002 - 2004
Creighton University School of MedicineClass of 2001

Certifications & Licensure

CA State Medical License 2003 - 2027
American Board of Internal Medicine Critical Care Medicine
American Board of Internal Medicine Pulmonary Disease

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013

Clinical Trials

Safety Study of Aztreonam Lysine for Inhalation (AZLI) in the Treatment of Early Bronchiolitis Obliterans Syndrome (BOS) Start of enrollment: 2013 Mar 01
Completed
Phase 4
Study to Assess the Efficacy and Safety of Simtuzumab (GS-6624) in Adults With Idiopathic Pulmonary Fibrosis (IPF) Start of enrollment: 2013 Jan 31
Terminated
Phase 2
Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease Prospective Outcomes Registry
RECRUITING
CLAD Phenotype Specific Risk Factors and Mechanisms Start of enrollment: 2015 Dec 22
Completed
Pulmonary Fibrosis Foundation Patient Registry Start of enrollment: 2016 Mar 29
Completed
Efficacy and Safety of Nintedanib in Patients With Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Start of enrollment: 2017 Jan 17
Completed
Phase 3
Scleroderma Lung Study III - Combining Pirfenidone With Mycophenolate Start of enrollment: 2017 Nov 28
Completed
Phase 2
A Trial to Evaluate the Safety of Long Term Treatment With Nintedanib in Patients With Scleroderma Related Lung Fibrosis Start of enrollment: 2017 Nov 27
Completed
Phase 3
Efficacy + Safety of Liposome Cyclosporine a to Treat Bronchiolitis Obliterans Post Single Lung Transplant (BOSTON-2) Start of enrollment: 2019 Mar 29
COMPLETED
PHASE3
Roles: Contact
Efficacy + Safety of Liposome Cyclosporine a to Treat Bronchiolitis Obliterans Post Single Lung Transplant (BOSTON-1) Start of enrollment: 2019 Apr 02
COMPLETED
PHASE3
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

Alterations in circulating measures of Th2 immune responses pre-lung transplant associates with reduced primary graft dysfunction.
Joanna M Schaenman, Stephen Samuel Weigt, Mengtong Pan, Joshua J Lee, Xinkai Zhou
The Journal of Heart and Lung Transplantation. 2024-11-01
Posaconazole and risk of cutaneous squamous cell carcinoma after lung transplantation: a single institution, retrospective cohort study.
Lawrence F Kuklinski, Alexandra M Klomhaus, Amy Shen, Natalie Achamallah, Teresa T Soriano
Archives of Dermatological Research. 2023-11-01
6 citations
Interstitial lung disease progression after genomic usual interstitial pneumonia testing.
Sachin Chaudhary, S Sam Weigt, Manuel L Ribeiro Neto, Bryan S Benn, Janelle Vu Pugashetti
The European Respiratory Journal. 2023-04-01

Grant Support

The Role Of Aspergillus In The Pathogenesis Of Bronchiolitis Obliterans SyndromeNational Heart, Lung, And Blood Institute2009–2011